Skip to content

Circulating Biomarkers and Ventricular Tachyarrhythmia

Circulating Biomarkers and Ventricular Tachyarrhythmia

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01892462
Acronym
LIFEMARKER
Enrollment
220
Registered
2013-07-04
Start date
2012-06-30
Completion date
2016-10-31
Last updated
2017-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiomyopathy, Ventricular Fibrillation, Ventricular Tachycardia

Brief summary

The purpose of this study is to determine whether levels of inflammatory markers in circulating blood can correlate with risk for dangerous heart rhythms. Patients with systolic heart failure, which has been shown to increase risk for dangerous heart rhythms, will be enrolled. All subjects will have an implantable cardioverter-defibrillator (ICD) in place, which allows regular evaluation of heart rhythm.

Detailed description

If you agree to be in this study, you will be asked to the following things: * you will come into the EP device clinic every three months for one year to have your device interrogated and will complete an EKG * you will have labs drawn to measure levels of certain markers of inflammation in the body. This information will be used to identify new ways to test for risk of abnormal heart rhythms and other heart disease * you will review your medications with the study coordinator and along with any recent illnesses or hospitalizations

Interventions

None listed

Sponsors

Boston Scientific Corporation
CollaboratorINDUSTRY
Ochsner Health System
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* left ventricular ejection fraction \[LVEF\] \<=35% * ICD implant

Exclusion criteria

* Recent myocardial infarction (12 weeks) * Recent revascularization (12 weeks) * Recent hospitalization for any cause (6 weeks) * History of rheumatologic disease

Design outcomes

Primary

MeasureTime frame
to evaluate a large population of heart failure patients with regard to circulating biomarkers and rates of subsequent ventricular arrhythmias.1 year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026